Johnson & Johnson (JNJ) Operating Expenses (2009 - 2026)
Johnson & Johnson (JNJ) posted Operating Expenses of $10.1 billion for Q2 2026, up 5.48% sequentially from $9.6 billion in Q1 2026, and up 6.86% YoY from $9.5 billion in Q2 2025.
Johnson & Johnson (JNJ) Operating Expenses (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Operating Expenses for 18 years, with the latest figure at $10.1 billion in Q2 2026.
- Quarterly Operating Expenses rose 6.86% year-over-year to $10.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $40.5 billion (up 0.93% YoY) and the FY2025 annual result came in at $38.6 billion, down 4.38% from the prior year.
- Operating Expenses grew to $10.1 billion in Q2 2026 per JNJ's latest filing, from $9.6 billion in the prior quarter.
- Over five years, Operating Expenses peaked at $11.8 billion in Q4 2024 and troughed at -$10.6 billion in Q1 2022.
- A 5-year average of $8.3 billion and a median of $9.5 billion in 2025 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2023: Operating Expenses tumbled 261.96% in 2022, then surged 143.61% in 2023.
- Over 5 years, Operating Expenses stood at $8.5 billion in 2022, then rose by 21.36% to $10.3 billion in 2023, then increased by 13.99% to $11.8 billion in 2024, then declined by 5.97% to $11.1 billion in 2025, then dropped by 8.75% to $10.1 billion in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $10.1 billion, $9.6 billion, and $11.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.90 Bn | 633.14 Bn | 17.26 Bn | 10.12 Bn |
| 2 | AbbVie | 470.19 Bn | 463.62 Bn | 12.70 Bn | 10.56 Bn |
| 3 | Merck | 377.19 Bn | 370.05 Bn | 12.21 Bn | 12.80 Bn |
| 4 | Novartis Ag | 303.28 Bn | 295.59 Bn | 11.24 Bn | 6.09 Bn |
| 5 | Astrazeneca | 257.67 Bn | 252.77 Bn | 12.86 Bn | 9.70 Bn |
| 6 | Amgen | 236.95 Bn | 222.96 Bn | 7.24 Bn | 6.54 Bn |
| 7 | Gilead Sciences | 182.20 Bn | 179.02 Bn | 6.22 Bn | 18.20 Bn |
| 8 | Pfizer | 159.32 Bn | 147.62 Bn | 10.94 Bn | 6.68 Bn |
| 9 | Gsk | 106.10 Bn | 101.93 Bn | 8.24 Bn | -7.60 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -5.98 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 10.12 Bn |
| Mar 29, 2026 | 9.59 Bn |
| Dec 28, 2025 | 11.09 Bn |
| Sep 28, 2025 | 9.66 Bn |
| Jun 29, 2025 | 9.47 Bn |
| Mar 30, 2025 | 8.35 Bn |
| Dec 29, 2024 | 11.79 Bn |
| Sep 29, 2024 | 10.47 Bn |
| Jun 30, 2024 | 9.11 Bn |
| Mar 31, 2024 | 8.96 Bn |
| Dec 31, 2023 | 10.35 Bn |
| Oct 1, 2023 | 9.01 Bn |
| Jul 2, 2023 | 9.24 Bn |
| Apr 2, 2023 | 8.49 Bn |
| Jan 1, 2023 | 4.25 Bn |
| Oct 2, 2022 | 8.53 Bn |
| Jul 3, 2022 | 10.01 Bn |
| Apr 3, 2022 | 9.47 Bn |
| Jan 2, 2022 | -10.56 Bn |
| Oct 3, 2021 | 9.48 Bn |